Wall Street analysts expect that Oxford Immunotec Global PLC (NASDAQ:OXFD) will announce sales of $19.44 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Oxford Immunotec Global’s earnings, with the lowest sales estimate coming in at $19.18 million and the highest estimate coming in at $19.93 million. Oxford Immunotec Global reported sales of $29.32 million in the same quarter last year, which would suggest a negative year over year growth rate of 33.7%. The company is expected to announce its next quarterly earnings results on Tuesday, July 30th.

According to Zacks, analysts expect that Oxford Immunotec Global will report full-year sales of $70.41 million for the current financial year, with estimates ranging from $70.16 million to $70.58 million. For the next year, analysts anticipate that the business will report sales of $81.49 million, with estimates ranging from $79.32 million to $82.86 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Oxford Immunotec Global.

Oxford Immunotec Global (NASDAQ:OXFD) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.14. The firm had revenue of $14.79 million for the quarter, compared to the consensus estimate of $13.74 million. Oxford Immunotec Global had a return on equity of 13.56% and a net margin of 172.27%. The company’s quarterly revenue was up 26.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.40) earnings per share.

OXFD has been the topic of a number of research analyst reports. Zacks Investment Research downgraded Oxford Immunotec Global from a “buy” rating to a “hold” rating in a report on Tuesday, March 19th. BidaskClub upgraded Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research report on Tuesday, May 7th. ValuEngine cut Oxford Immunotec Global from a “buy” rating to a “hold” rating in a research report on Monday, April 1st. Finally, Piper Jaffray Companies initiated coverage on Oxford Immunotec Global in a research report on Friday, March 8th. They set an “overweight” rating for the company.

Shares of NASDAQ:OXFD opened at $15.20 on Tuesday. The firm has a market cap of $406.00 million, a PE ratio of 29.80 and a beta of 0.32. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.03 and a current ratio of 12.60. Oxford Immunotec Global has a 1 year low of $11.66 and a 1 year high of $19.19.

In related news, CEO Peter Wrighton-Smith sold 10,600 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $16.68, for a total transaction of $176,808.00. Following the completion of the sale, the chief executive officer now owns 445,138 shares in the company, valued at $7,424,901.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Elizabeth M. Keiley sold 4,100 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $17.00, for a total value of $69,700.00. Following the sale, the senior vice president now owns 26,928 shares of the company’s stock, valued at approximately $457,776. The disclosure for this sale can be found here. In the last quarter, insiders have sold 17,700 shares of company stock valued at $294,658. 6.61% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of OXFD. Morgan Stanley increased its position in Oxford Immunotec Global by 238.7% in the first quarter. Morgan Stanley now owns 331,731 shares of the company’s stock worth $5,715,000 after buying an additional 233,797 shares in the last quarter. Man Group plc increased its position in Oxford Immunotec Global by 105.6% in the first quarter. Man Group plc now owns 356,624 shares of the company’s stock worth $6,145,000 after buying an additional 183,181 shares in the last quarter. Coastal Investment Advisors Inc. purchased a new stake in Oxford Immunotec Global in the first quarter worth about $35,000. Wellington Management Group LLP increased its position in Oxford Immunotec Global by 22.5% in the first quarter. Wellington Management Group LLP now owns 264,248 shares of the company’s stock worth $4,553,000 after buying an additional 48,598 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in Oxford Immunotec Global in the first quarter worth about $1,185,000. Institutional investors own 88.87% of the company’s stock.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

See Also: Do Tariffs Work?

Get a free copy of the Zacks research report on Oxford Immunotec Global (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.